Dose Calculator
Calculate precise medication doses
Introduction to GLP-1 Agonists
GLP-1 (Glucagon-Like Peptide-1) agonists represent a revolutionary class of medications that have transformed the treatment landscape for metabolic health and weight management. These compounds work by mimicking the effects of the natural GLP-1 hormone, which plays a crucial role in glucose regulation and appetite control.
Receptor Targeting Comparison
Semaglutide
GLP-1
GIP
Glucagon
Single receptor activation
Tirzepatide
GLP-1
GIP
Glucagon
Dual receptor activation
Retatrutide
GLP-1
GIP
Glucagon
Triple receptor activation
CagriSema
GLP-1
Amylin
GIP
Dual mechanism (GLP-1 + Amylin)
Receptor Binding & Mechanisms
94% GLP-1 Binding
Semaglutide
- Increases insulin secretion
- Reduces glucagon release
- Slows gastric emptying
- Reduces appetite via brain signaling
Tirzepatide
Dual Receptor Binding
- 92% binding affinity
- GIP Receptor
- Dual Action:
- Enhanced insulin sensitivity
- Greater appetite suppression
- Improved fat metabolism
- Synergistic receptor effects
Retatrutide
GLP-1 Receptor
- 91% binding affinity
- GIP Receptor
- Glucagon Receptor
- Triple Action:
- Maximum metabolic enhancement
- Increased energy expenditure
- Enhanced fat oxidation
- Potent appetite reduction
CagriSema
GLP-1 Receptor
- 94% (from semaglutide)
- Amylin Receptor
- Complementary Action:
- Dual pathway appetite control
- Enhanced satiety signaling
- Improved glucose handling
- Complementary receptor effects
Semaglutide
- Target: GLP-1 receptor only
- Dosing: 0.25mg to 2.4mg weekly
- Weight loss: 15-20% average
- Duration: 68-week trials
- Reconstitution Guide
Tirzepatide
- Targets: GLP-1 and GIP receptors
- Dosing: 2.5mg to 15.0mg weekly
- Weight loss: 20-25% average
- Duration: 72-week trials
- Reconstitution Guide
- FDA Updates
Retatrutide
- Targets: GLP-1, GIP, and Glucagon
- Triple receptor agonist
- Weight loss: 24-30% projected
- Phase 3 trials ongoing
- Enhanced metabolic effects
Emerging Compounds
- Cagrilintide: Amylin receptor
- Maritide: Enhanced GLP-1
- CagriSema: Dual mechanism
- Phase 2/3 trials ongoing
Clinical Evidence
Research demonstrates significant metabolic benefits across multiple studies:
- Semaglutide: 15-30kg (33-66 lbs) over 68 weeks
- Tirzepatide: 20-40kg (44-88 lbs) over 72 weeks
- Retatrutide: 25-45kg (55-99 lbs) projected
- Improved glycemic control in diabetic patients
- Cardiovascular benefits observed
- Sustainable results with continued treatment
For detailed analysis of test reports, see our test report guide.
Treatment Considerations
- Proper storage is crucial - see our storage guide
- Switching between compounds may require protocol adjustments - switching guide
- New users should review our getting started guide
- Regular monitoring recommended
- Individual response varies
Note: This article presents research analysis only. Always consult healthcare providers for medical decisions and treatment guidance.